Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.53 |
| ▸ | KDM6B | O15054 | 5/20 | 0.53 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | KDM4A | O75164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ASPH | Q12797 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30017034 | 1.00 | KDM4C (0.53) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| Hydrochloric Acid SCHEMBL1025670 | 0.98 | KDM4C (0.52) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL27138537 | 0.85 | KDM4C (0.50) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL30063342 | 0.85 | KDM4C (0.50) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL29369561 | 0.85 | POLB (0.54) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL379950 | 0.85 | POLB (0.54) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL31144930 | 0.83 | TDP1 (0.50) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL29460073 | 0.83 | POLB (0.52) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL1025669 | 0.83 | NPC1 (0.46) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| Hydrochloric Acid SCHEMBL3827644 | 0.83 | POLB (0.52) | KDM4CKDM6BKDM4DKDM4EKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295138-A1 | HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-21 | — | — | US | claimed |
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12534456-B2 | Heterocyclyl pyridines as novel fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-27 | — | — | US | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119569635-A | Biaryl ring inhibitors targeting c-Myc proteins | 上海深势唯思科技有限责任公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| EP-4347594-A1 | 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS | Genentech, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024054622-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-117355303-A | Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic disorders | 佛罗里达大学研究基金会公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2010125985-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | WO | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| EP-2097416-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen, Inc (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2008076425-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1912966-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB, S.A. (BE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1891042-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB Pharma, S.A. (BE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128692-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006128693-A2 | 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295138-A1 | HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES | PNPO, CBR3, HPD | KDM4C 170/4885KDM6B 268/4885KDM4D 376/4885 |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | KDM4C 3765/4885KDM6B 2826/4885KDM4D 3750/4885 |
| US-12534456-B2 | Heterocyclyl pyridines as novel fungicides | CBR1, CBR3, NOX1 | KDM4C 284/4885KDM6B 277/4885KDM4D 1352/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | KDM4C 4395/4885KDM6B 4467/4885KDM4D 4123/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | KDM4C 2565/4885KDM6B 2657/4885KDM4D 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.